CD274 and non-small cell lung carcinoma: Additionally, the anatomic site treated with radiation could influence the side effect profile of combination treatment; for instance, the landmark PACIFIC trial, which demonstrated a significant overall survival benefit to adjuvant durvalumab (an anti-PD-L1 antibody) after definitive chemoradiation for stage III NSCLC, also showed an increase in any-grade pneumonitis with the addition of durvalumab (although rates of clinically relevant pneumonitis, i.e. grade 3+, were similar between treatment groups and low overall) (57).